Avanos Medical, Inc. (AVNS): Business Model Canvas [Jan-2025 Mis à jour]

Dans le paysage dynamique de la technologie médicale, Avanos Medical, Inc. (AVNS) émerge comme une force transformatrice, naviguant stratégiquement dans l'écosystème de soins de santé complexe grâce à son modèle commercial méticuleusement conçu. En intégrant de manière transparente des solutions innovantes de gestion de la douleur, des interventions chirurgicales avancées et des technologies de dispositifs médicaux de pointe, Avanos s'est positionné comme un acteur pivot pour fournir des innovations de soins de santé centrées sur le patient. Cette toile complète du modèle commercial révèle le cadre stratégique complexe qui propulse le succès remarquable d'Avns, offrant un aperçu sans précédent de la façon dont l'entreprise crée systématiquement, offre et capture la valeur dans l'industrie des dispositifs médicaux hautement compétitifs.

Avanos Medical, Inc. (AVNS) - Modèle d'entreprise: partenariats clés

Fabricants de dispositifs médicaux stratégiques

Avanos Medical collabore avec les fabricants de dispositifs médicaux stratégiques suivants:

Partenaire	Focus de partenariat	Année établie
Santé cardinale	Chaîne d'approvisionnement et distribution	2018
Industries Medline	Approvisionnement des dispositifs médicaux	2019

Distributeurs et fournisseurs de soins de santé

Les principaux partenariats de distribution de soins de santé comprennent:

• Amerisourcebergen
• McKesson Corporation
• Henry Schein Medical

Institutions de recherche et universités

Avanos Medical Research Collaboration Partners:

Institution	Domaine de recherche	Valeur de collaboration
Université Johns Hopkins	Technologies de gestion de la douleur	2,3 millions de dollars par an
École de médecine de Stanford	Innovation chirurgicale	1,7 million de dollars par an

Centres chirurgicaux et hôpitaux

Partenariats du réseau hospitalier d'Avanos Medical:

• Clinique de mayo
• Clinique de Cleveland
• NYU Langone Health

Partenaires de l'innovation en technologie médicale

Détails de collaboration sur l'innovation technologique:

Partenaire	Focus de l'innovation	Investissement
Medtronic	Solutions avancées de gestion de la douleur	Investissement de R&D de 5,6 millions de dollars
Boston Scientific	Technologies interventionnelles	4,2 millions de dollars de recherche collaborative

Avanos Medical, Inc. (AVNS) - Modèle d'entreprise: activités clés

Recherche et développement des dispositifs médicaux

Investissement en R&D en 2023: 74,2 millions de dollars

Zones de mise au point R&D	Pourcentage d'investissement
Technologies de gestion de la douleur	42%
Produits interventionnels chirurgicaux	33%
Solutions respiratoires avancées	25%

Conception avancée de la solution de gestion de la douleur

Portfolio total de produits de gestion de la douleur: 17 dispositifs médicaux spécialisés

• Systèmes d'intervention de la douleur chronique
• Technologies de gestion de la douleur aiguë
• Solutions de blocs nerveux et d'anesthésie régionale

Fabrication de produits chirurgicaux et interventionnels

Capacité de fabrication annuelle: 2,4 millions de dispositifs médicaux

Lieux de fabrication	Volume de production
États-Unis	1,6 million d'unités
Mexique	0,8 million d'unités

Contrôle de la qualité et conformité réglementaire

Certifications réglementaires: FDA, ISO 13485: 2016

• Fréquence d'audit de qualité annuelle: 4 fois par an
• Investissement de conformité: 22,3 millions de dollars en 2023
• Personnel de contrôle de la qualité: 126 spécialistes

Marketing et ventes de produits médicaux

2023 Budget marketing: 98,6 millions de dollars

Canal de vente	Contribution des revenus
Ventes directes	62%
Réseau de distribution	38%

Avanos Medical, Inc. (AVNS) - Modèle d'entreprise: Ressources clés

Expertise spécialisée en génie médical

En 2024, Avanos Medical emploie environ 2 200 professionnels ayant des antécédents spécialisés en génie médical. L'équipe d'ingénierie de l'entreprise détient 272 brevets actifs dans les technologies de dispositifs médicaux.

Installations de fabrication avancées

Emplacement	Taille de l'installation	Capacité de production
Austin, Texas	85 000 pieds carrés	3,2 millions d'appareils médicaux par an
Alpharetta, Géorgie	65 000 pieds carrés	2,7 millions d'appareils médicaux par an

Propriété intellectuelle et brevets de dispositifs médicaux

Le portefeuille de brevets actuel comprend:

• 272 brevets de dispositifs médicaux actifs
• 87 demandes de brevet en instance
• Évaluation des brevets estimée à 124 millions de dollars

Équipe de recherche et de développement

Investissement en R&D en 2023: 87,3 millions de dollars, représentant 6,4% du total des revenus de l'entreprise.

Infrastructure de technologie médicale

Investissements infrastructures technologiques:

• Infrastructure de cloud computing: 12,4 millions de dollars
• Systèmes d'imagerie médicale avancés: 9,7 millions de dollars
• Plateformes de recherche sur l'IA et l'apprentissage automatique: 6,2 millions de dollars

Avanos Medical, Inc. (AVNS) - Modèle d'entreprise: propositions de valeur

Solutions de dispositifs médicaux innovants

Avanos Medical, Inc. a déclaré un chiffre d'affaires total de 812,4 millions de dollars pour l'exercice 2022. Les solutions de dispositifs médicaux innovantes de la société se concentrent sur des gammes de produits spécialisées dans plusieurs segments de soins de santé.

Catégorie de produits	Contribution des revenus	Segment de marché
Dispositifs chirurgicaux	342,6 millions de dollars	Solutions de salle d'opération
Technologies de gestion de la douleur	270,8 millions de dollars	Gestion de la douleur interventionnelle
Produits de soins respiratoires	199 millions de dollars	Soins à l'hôpital et à la maison

Technologies avancées de gestion de la douleur

Avanos Medical est spécialisé dans les technologies de gestion de la douleur en mettant l'accent sur les solutions interventionnelles.

• COFFACE * Traitement radiofréquence refroidi: pénétration du marché de 17% dans le segment chronique de la gestion de la douleur
• Systèmes de cathéter de blocs nerveux avancé avec une note d'efficacité clinique à 92%
• Portefeuille de gestion de la douleur propriétaire générant 270,8 millions de dollars de revenus annuels

Produits d'intervention chirurgicale de haute qualité

La gamme de produits d'intervention chirurgicale génère des revenus importants avec des technologies médicales précises.

Gamme de produits chirurgicaux	Part de marché	Revenus annuels
Dispositifs de fermeture des plaies chirurgicales	12.5%	156,3 millions de dollars
Systèmes de drainage chirurgical	8.7%	112,4 millions de dollars

Innovations de soins de santé centrés sur le patient

Avanos Medical a investi 64,2 millions de dollars dans la recherche et le développement en 2022, en se concentrant sur des solutions médicales centrées sur le patient.

• 3 nouveaux brevets déposés dans les technologies de surveillance des patients
• Taux de réussite des essais cliniques de 76% pour les nouveaux dispositifs médicaux
• Évaluation de satisfaction des patients de 94% entre les gammes de produits

Conception de l'équipement médical de précision

Approche de conception de précision soutenue par des investissements de recherche substantiels.

Investissement de conception	Taille de l'équipe d'ingénierie	Cycle de développement des produits
Budget de R&D de 64,2 millions de dollars	387 professionnels de l'ingénierie	18-24 mois par produit

Avanos Medical, Inc. (AVNS) - Modèle d'entreprise: relations avec les clients

Équipes de soutien aux ventes directes

Avanos Medical maintient 127 représentants des ventes directes au quatrième trimestre 2023, couvrant les établissements de santé à travers les États-Unis. Rémunération du représentant des ventes annuelles moyennes: 185 700 $.

Métrique de l'équipe de vente	2023 données
Représentants des ventes totales	127
Compensation annuelle moyenne	$185,700
Couverture géographique	États-Unis

Consultation technique en produits médicaux

Taille de l'équipe de consultation technique: 42 experts en produit médical spécialisés. Temps de réponse moyen pour les demandes techniques: 2,4 heures.

• Disponibilité du support technique 24/7
• Services de consultation multilingues
• Durée moyenne de consultation d'experts: 47 minutes

Plateformes de service client en ligne

Les canaux de service client numérique comprennent:

• Portail Web avec une disponibilité de 99,7%
• Téléchargements des applications mobiles: 42 500 en 2023
• Temps de résolution d'interaction numérique moyen: 3,2 heures

Programmes de formation professionnelle médicale

Métrique du programme de formation	2023 données
Sessions de formation totales	218
Les participants formés	3,642
Durée de formation moyenne	6,5 heures

Support de dispositif médical personnalisé

Métriques de soutien personnalisées:

• Gestionnaires de compte dédiés: 87
• Évaluation de satisfaction du client: 94,3%
• Temps de personnalisation moyen de l'appareil: 5,6 jours

Avanos Medical, Inc. (AVNS) - Modèle d'entreprise: canaux

Force de vente directe

En 2024, Avanos Medical maintient une équipe de vente interne dédiée d'environ 287 représentants des ventes directes axées sur les marchés chirurgicaux et interventionnels.

Catégorie de canal de vente	Nombre de représentants	Segment du marché cible
Équipe de vente chirurgicale	162	Hôpitaux et centres chirurgicaux
Équipe de vente interventionnelle	125	Cliniques médicales spécialisées

Réseaux de distributeurs de dispositifs médicaux

Avanos médical s'associe à 73 distributeurs nationaux et internationaux de dispositifs médicaux dans 12 pays.

• Réseau de distribution nord-américain: 42 distributeurs
• Réseau de distribution européen: 19 distributeurs
• Réseau de distribution Asie-Pacifique: 12 distributeurs

Plateformes de commerce électronique en ligne

Les canaux de vente numériques génèrent 47,3 millions de dollars de revenus annuels pour Avanos Medical en 2024.

Plate-forme de commerce électronique	Volume des ventes annuelles	Pourcentage de revenus numériques
Site Web de l'entreprise directe	22,6 millions de dollars	47.8%
Marchés médicaux tiers	24,7 millions de dollars	52.2%

Expositions de la conférence médicale

Avanos Medical participe à 37 conférences médicales par an, avec un investissement estimé à l'exposition de 2,1 millions de dollars.

Marketing numérique professionnel de la santé

Budget de marketing numérique alloué: 6,5 millions de dollars en 2024, ciblant les professionnels de la santé sur plusieurs canaux numériques.

Canal de marketing numérique	Budget alloué	Public cible
Publicité professionnelle LinkedIn	2,3 millions de dollars	Médecins et administrateurs de soins de santé
Plateformes Web médicales spécialisées	1,8 million de dollars	Médecin spécialiste
Publicité numérique programmatique	2,4 millions de dollars	Large segment professionnel de la santé

Avanos Medical, Inc. (AVNS) - Modèle d'entreprise: segments de clients

Hôpitaux et centres chirurgicaux

En 2023, Avanos Medical dessert environ 5 600 hôpitaux aux États-Unis. La pénétration du marché de l'entreprise comprend:

Type d'hôpital	Nombre d'installations	Pénétration du marché
Grands centres médicaux académiques	287	82%
Hôpitaux communautaires	4,813	65%
Hôpitaux chirurgicaux spécialisés	500	73%

Anesthésiologistes et spécialistes de la gestion de la douleur

Avanos Medical cible environ 52 000 anesthésiologistes pratiquants aux États-Unis.

• Valeur du segment du marché de la gestion de la douleur: 71,3 milliards de dollars en 2023
• Base de clientèle spécialisée: 18 500 praticiens de la gestion de la douleur
• Pouvoir d'achat annuel des produits par spécialiste: 157 000 $

Médecins interventionnels

Répartition du segment des clients pour les spécialistes interventionnels:

Spécialité	Nombre de pratiquants	Dépenses annuelles moyennes de produits
Radiologues interventionnels	6,200	$94,500
Cardiologues interventionnels	8,700	$112,300

Services d'achat de soins de santé

Le segment de clientèle d'approvisionnement d'Avanos Medical comprend:

• Organisations d'achat de groupe (GPO): 8 réseaux nationaux majeurs
• Total des services d'approvisionnement desservis: 3 200
• Valeur du contrat annuel: 42,6 millions de dollars

Centres chirurgicaux ambulatoires

Détails du segment de marché pour les centres chirurgicaux ambulatoires:

Type de centre	Centres totaux	Pénétration du marché d'Avanos	Contribution annuelle des revenus
ASC orthopédique	4,100	57%	23,4 millions de dollars
ASC multi-spécialités	5,600	49%	18,7 millions de dollars

Avanos Medical, Inc. (AVNS) - Modèle d'entreprise: Structure des coûts

Investissements de recherche et développement

Pour l'exercice 2022, Avanos Medical, Inc. a investi 40,5 millions de dollars dans les frais de recherche et de développement, représentant 6,1% des revenus totaux.

Année	Investissement en R&D	Pourcentage de revenus
2022	40,5 millions de dollars	6.1%
2021	38,2 millions de dollars	5.8%

Frais de fabrication et de production

Les coûts de fabrication totaux pour Avanos Medical en 2022 étaient d'environ 261,7 millions de dollars, ce qui comprend la main-d'œuvre directe, les matériaux et les frais généraux.

• Coûts de matériel direct: 142,3 millions de dollars
• Coûts de main-d'œuvre directs: 63,5 millions de dollars
• Fabrication des frais généraux: 55,9 millions de dollars

Dépenses de vente et de marketing

Les dépenses de vente et de marketing d'Avanos Medical en 2022 ont totalisé 146,3 millions de dollars, ce qui représente 22% des revenus totaux.

Catégorie de dépenses	Montant
Coûts du personnel de vente	82,7 millions de dollars
Campagnes marketing	38,5 millions de dollars
Infrastructure de soutien aux ventes	25,1 millions de dollars

Coûts de conformité réglementaire

Les dépenses de conformité réglementaire pour Avanos Medical en 2022 étaient de 23,6 millions de dollars, ce qui comprend des activités d'assurance qualité, de certification et de conformité juridique.

Maintenance des infrastructures technologiques

Les coûts de maintenance de la technologie et de l'infrastructure informatique pour 2022 s'élevaient à 32,4 millions de dollars, couvrant les logiciels, le matériel, la cybersécurité et les investissements d'infrastructure numérique.

Catégorie de coûts technologiques	Montant
Licence de logiciel	12,6 millions de dollars
Infrastructure matérielle	9,8 millions de dollars
Investissements en cybersécurité	6,5 millions de dollars
Initiatives de transformation numérique	3,5 millions de dollars

Avanos Medical, Inc. (AVNS) - Modèle d'entreprise: Strots de revenus

Ventes de produits de dispositif médical

Exercice 2022 Revenu total: 806,4 millions de dollars

Catégorie de produits	Revenus ($ m)	Pourcentage
Gestion de la douleur chronique	$380.2	47.1%
Gestion de la douleur interventionnelle	$276.5	34.3%
Produits chirurgicaux	$149.7	18.6%

Revenus d'équipement d'intervention chirurgicale

2022 Revenus de l'équipement chirurgical: 149,7 millions de dollars

• Produits de drainage chirurgical spécialisés
• Solutions de gestion des plaies chirurgicales
• Technologies d'intervention chirurgicale avancées

Licence de solution de gestion de la douleur

Revenus de licence pour 2022: 42,3 millions de dollars

Catégorie de licence	Revenus ($ m)
Technologie de douleur chronique	$28.6
Solutions de douleur interventionnelle	$13.7

Contrats de services de technologie médicale

Revenus de contrat de service pour 2022: 33,5 millions de dollars

• Maintenance des dispositifs médicaux
• Accords de support technique
• Services d'installation et de formation

Frais de maintenance des produits récurrents

Revenus de frais de maintenance pour 2022: 22,9 millions de dollars

Type de maintenance	Revenus ($ m)
Dispositifs de douleur chronique	$14.6
Entretien des équipements chirurgicaux	$8.3

Avanos Medical, Inc. (AVNS) - Canvas Business Model: Value Propositions

You're looking at the core reasons why customers choose Avanos Medical, Inc. (AVNS) products, grounded in their late 2025 performance data. The value propositions center on clinical differentiation and strategic portfolio focus.

Opioid-sparing, non-invasive chronic pain relief (RFA)

Avanos Medical, Inc. offers Radiofrequency Ablation (RFA) solutions as a key component in addressing the need for alternatives to systemic opioids for pain management. The momentum in this area is clear from recent results.

• Net sales of RFA products grew by 10.5% in the third quarter of 2025.
• The overall Pain Management & Recovery (PM&R) segment net sales for Q3 2025 were $59.0 million, an increase of $1.2 million versus the prior year period.
• This growth reflects sustained momentum in RFA generator sales, which directly resulted in higher procedural volumes across their product lines.

Life-sustaining enteral feeding and neonatal solutions

The Specialty Nutrition Systems (SNS) segment provides vital support for patients requiring long-term nutrition, including neonates. This segment is a primary growth engine for Avanos Medical, Inc.

• SNS achieved 14.5% organic growth in the third quarter of 2025.
• For the first nine months of 2025, SNS net sales reached $317.8 million, representing an increase of $27.3 million compared to the prior year period, driven by 9.1% volume growth.
• The NeoMed product offering, part of the neonatal solutions, exceeded $100 million of annualized revenue as of December 2024, maintaining the number one share position in the US.
• Operating income for the SNS segment for the first nine months of 2025 was $62.1 million, which is 19.5% of SNS net sales.

Safer, more consistent nutrition/medication delivery

Avanos Medical, Inc. focuses on improving the reliability and safety of feeding delivery, particularly through standardization and technology adoption.

The value here is tied to preventing adverse events and ensuring proper nutrient uptake, supported by specific product adoption metrics.

• Short-term feeding portfolio growth is driven by the continued expansion of their US CORTRAK standard of care offerings.
• The shift to new alternatives like the ENFit connectors helps prevent hospital-never events, a critical safety metric in feeding.
• Reimbursement for long-term feeding patients in the US is described as robust and not expected to change soon.

Clinically superior, evidence-based medical devices

The company emphasizes that its devices offer superior clinical outcomes, which drives adoption, especially in the enteral feeding space where CORTRAK is mentioned as a standard of care offering.

Here's a quick look at the segment performance that underpins the overall financial health, which supports continued R&D and market presence:

Metric (As of 9M 2025)	Value	Segment
Total Net Sales	$520.3 million	Company-wide
Total Net Sales Growth (vs prior year)	2.4%	Company-wide
Adjusted Gross Margin (Q3 2025)	52.8%	Company-wide
RFA Product Net Sales Growth (Q3 2025)	10.5%	PM&R
SNS Segment Operating Profit Margin (9M 2025)	19.5%	SNS

Focus on high-growth, core segments for investors

Avanos Medical, Inc. is actively refining its portfolio to concentrate capital and resources on areas with the highest growth potential, signaling a clear strategic direction for investors.

This focus is evidenced by recent portfolio management actions:

• The company announced the divestiture of its Hyaluronic Acid (HA) business on July 31, 2025.
• They are executing an exit from the IV infusion products category, planned for early 2026.
• The acquisition of Nexus Medical is expected to be immediately accretive and provides access to a $70 million market segment.
• Management has initiated a $15 million-$20 million cost savings initiative.
• The full-year 2025 revenue estimate was raised to a range of $690 million to $700 million, with the adjusted EPS estimate raised to $0.85 to $0.95 per share.

Finance: draft 13-week cash view by Friday.

Avanos Medical, Inc. (AVNS) - Canvas Business Model: Customer Relationships

You're looking at how Avanos Medical, Inc. (AVNS) builds and maintains its ties with the people and institutions that buy its products. This isn't just about transactions; it's about deep integration, especially in specialized areas like pain management and nutrition.

Dedicated clinical training and support for RFA procedures

Avanos Medical, Inc. supports its Radiofrequency Ablation (RFA) solutions with a history of clinical engagement. The company notes having over 20 years of experience working with leading institutions to develop successful pain management programs. The focus here is on ensuring providers can use the technology effectively, which is critical for procedures where patient outcomes are paramount. For instance, the momentum in RFA generator sales, which drove RFA product net sales growth of 10.9% for the nine months ended September 30, 2025, relies on this support structure.

The relationship is reinforced through educational efforts, such as hosting industry symposiums like the one at ASRA 2025, focusing on opioid-sparing therapies.

Long-term contracts with major hospital systems/IDNs

While specific contract values aren't public, the relationship strategy involves deep integration within hospital systems. The growth in the Pain Management & Recovery (PM&R) segment, which saw net sales of $176.2 million for the nine months ended September 30, 2025, reflects ongoing engagement with these facilities. The company's portfolio, including RFA products, is positioned to support hospital operations by offering evidence-based, non-narcotic solutions for chronic pain management, which is a key concern for hospital administrators focused on efficiency and reputation.

Direct-to-patient support for chronic care products

For its Specialty Nutrition Systems (SNS) segment, which provides a lifeline for nutrition from hospital to home, Avanos Medical, Inc. is taking steps to enhance direct control over the customer experience. A concrete action in this area is the expansion of direct operations for MIC-KEY enteral feeding products into the United Kingdom, effective July 2025. This move signals a commitment to a more direct relationship with the end-user base for chronic care. The SNS segment showed strong performance, with net sales of $317.8 million and 9.1% volume growth for the first nine months of 2025.

High-touch, consultative sales for capital equipment

The sales approach for capital equipment, like RFA generators, is consultative, focusing on providing a full suite of options-cooled, 3-tined, and conventional RFA-to tailor treatment plans. This consultative model supports the sales momentum seen in the PM&R segment. The company has a dedicated sales force and customer support team with significant industry experience and product training supporting its franchises.

Digital tools for product reordering and education

Avanos Medical, Inc. is focused on operational optimization, which includes digital components, though specific usage metrics for reordering aren't detailed. The company's overall transformation priorities through 2025 included strategic and commercial optimization. The company employs more than 2,200 people worldwide, supporting its global footprint and product marketing efforts. The overall net sales for the last twelve months ending September 30, 2025, reached $699.90 million.

Here's a quick look at the scale of the business supporting these relationships as of late 2025:

Metric	Value (Latest Reported Period)
Total Net Sales (Last Twelve Months ending Q3 2025)	$699.90 million
SNS Segment Net Sales (9 Months ended Sep 30, 2025)	$317.8 million
PM&R Segment Net Sales (9 Months ended Sep 30, 2025)	$176.2 million
RFA Product Net Sales Growth (9 Months ended Sep 30, 2025)	10.9%
Total Employees Worldwide (As of 2024)	More than 2,200

The company's 2025 estimated revenue guidance was set between $665 million and $685 million.

The relationship strategy is supported by a structure that includes:

• A dedicated sales force for each franchise.
• Customer support teams with significant industry experience.
• A medical education program with HCP-led training.
• Local, in-person support and training availability.

Finance: draft 13-week cash view by Friday.

Avanos Medical, Inc. (AVNS) - Canvas Business Model: Channels

You're looking at how Avanos Medical, Inc. gets its clinically superior medical device solutions into the hands of healthcare providers and patients as of late 2025. The channel strategy is clearly evolving, moving toward more direct control where it makes strategic sense, while still relying on established networks for broad reach.

Here's a quick look at the top-line financial context for the channels to consider:

Metric	Value (as of late 2025)	Period/Date
Trailing 12-Month Revenue	$700 Million USD	As of September 30, 2025
Full-Year 2025 Net Sales Guidance (Raised)	$690 Million to $700 Million	Updated Guidance
Q3 2025 Enteral Feeding Unit Revenue	$82.7 Million	Q3 2025
Q3 2025 Neonate Solutions Unit Revenue	$31.3 Million	Q3 2025

The company develops, manufactures, and markets its recognized brands globally, holding leading market positions in multiple product categories across its portfolio.

Direct sales force to hospitals and ASCs

Avanos Medical, Inc. markets its products generally directly to hospitals and other healthcare providers. This direct engagement is crucial for complex devices and capital equipment sales, especially within the Pain Management & Recovery (PM&R) segment, which includes Radiofrequency Ablation (RFA) generator sales that grew 10.5% year over year in Q3 2025 to $34.6 million. The direct sales effort supports the company's commitment to reducing opioid use and helping patients move from surgery to recovery.

Third-party medical device distributors globally

While pushing for direct relationships, a significant portion of sales still flows through third-party wholesale distributors. For the year ended December 31, 2024, approximately 50% of North America net sales were executed via these distributors. Two major distributors, McKesson Corporation and Medline Industries, accounted for approximately 18% and 17% of consolidated net sales in 2024, respectively. Globally, the MIC-KEY product line, which is part of the Specialty Nutrition Systems (SNS) segment, is sold in over 60 countries across six continents.

Direct-to-home patient supply for chronic care

A key part of the Avanos Medical mission involves providing a vital lifeline for nutrition to patients from hospital to home. This is primarily served through the Chronic Care franchise, now integrated into the Digestive Health focus within the combined commercial organization. The Enteral feeding unit, which supports this continuum of care, generated net sales of $82.7 million in the third quarter of 2025, representing a 14.9% increase year over year.

Strategic transition to direct operations (e.g., UK MIC-KEY)

Avanos Medical, Inc. is actively strengthening its direct control over key product lines. A major example is the strategic transition for the MIC-KEY enteral feeding products in the United Kingdom. Effective July 25, 2025, Avanos took direct responsibility for sales and distribution, ending a 29-year distribution partnership with Vygon UK. This move is intended to enhance customer relationships and improve service efficiency by eliminating the intermediary.

E-commerce and online portals for consumables

The company is focused on go-to-market strategies to accelerate growth, which includes enhancing customer engagement. The channels used for consumables, which are typically lower-touch items supporting the core devices, are increasingly being managed through digital means. The company plans to guide healthcare facilities through new ordering processes following the UK transition to ensure continuity.

• The company is focused on advancing its strategic segments in PM&R and SNS following the July 2025 divestiture of its Hyaluronic Acid (HA) product line.
• The SNS segment saw volume growth of 14% in Q3 2025, driven by long-term feeding products.
• The company's overall strategy involves commercial optimization and supply chain effectiveness.
• The direct control in the UK aims to ensure uninterrupted access to MIC-KEY products.

Avanos Medical, Inc. (AVNS) - Canvas Business Model: Customer Segments

Hospitals and Integrated Delivery Networks (IDNs)

• SNS segment net sales for the third quarter of 2025 totaled $114.0 million.
• PM&R segment net sales for the third quarter of 2025 totaled $59 million.
• The Specialty Nutrition Systems (SNS) segment recorded volume growth of 14.0% in the third quarter of 2025.
• The full-year 2025 revenue guidance is between $690 million and $700 million.

Pain management specialists and anesthesiologists

Pain Management Sub-Segment	Q3 2025 Net Sales (in millions)	Year-over-Year Change
Radiofrequency Ablation (RFA) products	$34.60 million	Up 10.5%
Surgical pain and recovery	$24.40 million	Down 7.9%

Neonatal and Pediatric Intensive Care Units (NICUs/PICUs)

• Neonate solutions unit revenue for the third quarter of 2025 amounted to $31.3 million.
• Neonate solutions revenue growth year-over-year for the third quarter of 2025 was 19.5%.
• Avanos Medical, Inc. completed the acquisition of Nexus Medical, which is expected to deliver immediate value in NICU and PICU care.

Patients requiring long-term enteral feeding

• Enteral feeding unit revenue for the third quarter of 2025 totaled $82.70 million.
• Enteral feeding revenue growth year-over-year for the third quarter of 2025 was 14.9%.
• The company noted strong demand for its long-term feeding products in the third quarter of 2025.

Ambulatory Surgery Centers (ASCs) for RFA procedures

• RFA product net sales grew 10.5% year-over-year in the third quarter of 2025.
• RFA capital equipment sales drove procedural volumes in the third quarter of 2025.
• The Radiofrequency Ablation (RFA) business posted double-digit growth in the third quarter of 2025 compared to the previous year.

Avanos Medical, Inc. (AVNS) - Canvas Business Model: Cost Structure

You're looking at the cost side of the Avanos Medical, Inc. (AVNS) engine as of late 2025. It's a mix of necessary investment for growth, the lingering effects of external pressures, and costs tied to strategic restructuring. Honestly, keeping the lights on and investing for the future requires significant outlay across the board.

High Cost of Goods Sold (COGS) due to tariff headwinds

Tariffs are definitely biting into the gross margin. For the second quarter of 2025, the reported gross profit margin was 52.6%, a notable drop from 55.7% in the prior year period. Management specifically cited higher tariffs as a primary driver for this contraction, alongside lower pricing on the Hyaluronic Acid (HA) products before that line was divested. Looking ahead, the full-year 2025 free cash flow forecast is explicitly inclusive of an estimated $18 million tariff impact. The company is actively working on mitigation, including supply-chain relocation and a plan to exit China for neonatal syringe production by mid-2026, which is driving higher capital expenditures in 2025.

Significant R&D and SG&A investment for core growth

Investing in the core segments-Specialty Nutrition Systems (SNS) and Pain Management & Recovery (PM&R)-means keeping R&D and SG&A spending at meaningful levels. You see the discipline in the latest quarterly figures, but the absolute spend is still substantial. Here's a snapshot of the most recent reported operating expenses from the third quarter of 2025:

Expense Category	Q3 2025 Amount	Year-over-Year Change	Context/Metric
Selling and General Expenses	$83.5 million	Increased 3.2%	Reported for the quarter
Research and Development Expenses	$5.8 million	Decreased 7.9%	Reported for the quarter
Adjusted SG&A as % of Revenue	40.6%	N/A	Q3 2025 metric
SG&A as % of Net Sales (Full Year 2024)	46.3%	Decreased from 49.8%	Driven by transformation and divestiture costs

The company is streamlining management and revamping R&D with a hybrid model to accelerate product development, aiming for $15 million to $20 million in run-rate annualized cost savings by 2026.

Transformation costs, including $10 million one-time Q4 2025 charges

The ongoing transformation process, initiated in January 2023, carries specific one-time costs. Management anticipates approximately $10 million in one-time cash charges related to expanded cost programs, with the majority expected to be incurred in 2025. This $10 million in transformation-related charges is explicitly factored into the full-year 2025 free cash flow forecast of $25 million-$30 million.

Manufacturing and supply chain expenses

While specific manufacturing cost line items aren't broken out separately from COGS, supply chain expenses are embedded within the margin pressures and capital expenditure plans. The company is focused on improving profitability in certain areas, such as transitioning the Game Ready U.S. Rental segment to a distribution arrangement with WRS Group. Furthermore, capital expenditures are higher in 2025 to support the planned exit from China for neonatal syringe production by mid-2026.

Amortization of acquired intangibles (e.g., Nexus Medical)

Amortization of intangible assets, stemming from prior business acquisitions, is a consistent non-cash cost. The most recent reported figure for this expense in the second quarter of 2025 was $3.0 million on an adjusted, non-GAAP basis. For comparison, the full-year 2024 amortization was $25.2 million. The recent acquisition of Nexus Medical is expected to be immediately accretive to revenue and earnings per share, meaning its related amortization will be a new component of the cost structure moving forward.

You should track the quarterly non-GAAP intangibles amortization:

• Q2 2025: $3.0 million
• Q1 2025: $2.9 million
• Full Year 2024: $25.2 million

Finance: draft 13-week cash view by Friday.

Avanos Medical, Inc. (AVNS) - Canvas Business Model: Revenue Streams

You're looking at the core ways Avanos Medical, Inc. brings in money as of late 2025, which is heavily influenced by their recent strategic moves and acquisitions.

The company has officially raised and narrowed its full-year 2025 revenue guidance following the third quarter results.

Revenue Component	Latest Reported Period Data (Q3 2025)	FY 2025 Guidance/Estimate
Total Net Sales (FY 2025 Estimate)	$177.8 million (Q3 Actual)	$690 million to $700 million
Specialty Nutrition Systems (SNS) Net Sales	$114 million	Part of Total Guidance
Pain Management & Recovery (PM&R) Net Sales	$59 million	Part of Total Guidance
Radiofrequency Ablation (RFA) Product Sales	$34.6 million (Q3 Actual)	Q2 2025 Growth: 13.7%
Nexus Medical Acquisition Accretion	N/A (Acquisition closed 9/15)	Roughly $5 million in 2025

Sales of Specialty Nutrition Systems (SNS) products remain a primary driver, showing strong momentum.

• SNS segment recorded net sales of $114 million in the third quarter of 2025.
• This reflected 14% volume growth in the third quarter.
• The segment saw double-digit growth, anchored by enteral feeding and neonate solutions.

Revenue from Pain Management & Recovery (PM&R) devices and consumables is also critical, though it includes a mixed performance across its sub-categories.

The Radiofrequency Ablation (RFA) business within PM&R is a key growth area for device sales.

• Net sales of RFA products grew 10.5% year-over-year in Q3 2025, reaching $34.6 million.
• This follows a reported 13.7% growth rate for RFA product sales in the second quarter of 2025.
• The segment's overall growth was partially offset by a year-over-year decline of 7.9% in surgical pain and recovery unit sales.

Furthermore, the recent strategic move to acquire Nexus Medical is expected to contribute directly to the top line.

Revenue accretion from the Nexus Medical acquisition is factored into the full-year estimate, expected to contribute roughly $5 million to the 2025 total revenue figure. Finance: review the Q4 forecast to ensure the $5 million accretion is fully captured within the $690-$700 million range by Friday.